Christopher Cannon

Summary

Affiliation: Massachusetts General Hospital
Country: USA

Publications

  1. ncbi Evolving management of ST-segment elevation myocardial infarction: update on recent data
    Christopher P Cannon
    Thrombolysis in Myocardial Infarction TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA
    Am J Cardiol 98:10Q-21Q. 2006
  2. ncbi Clinical trials update from the annual scientific session of the American College of Cardiology 2006
    Christopher P Cannon
    Thrombolysis in Myocardial Infarction Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA
    Am J Cardiol 98:36Q-41Q. 2006
  3. ncbi Introduction: rationale for tight control of hyperglycemia
    Christopher P Cannon
    The Thrombolysis in Myocardial Infarction (TIMI) Study Group, Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, 75 Francis Street, Boston, Massachusetts 02115, USA
    Am J Cardiol 99:1H-4H. 2007
  4. ncbi Outcomes of patients with acute coronary syndrome and previous coronary artery bypass grafting (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy [PROVE IT-TIMI 22] and the Aggrastat to Zocor [A to Z] trials)
    Emmanouil S Brilakis
    Cardiovascular Division, Department of Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA
    Am J Cardiol 102:552-8. 2008
  5. ncbi Reduction in First and Recurrent Cardiovascular Events With Ticagrelor Compared With Clopidogrel in the PLATO Study
    Payal Kohli
    TIMI Study Group Cardiovascular Division, Brigham and Women s Hospital, 350 Longwood Avenue, 1 floor office, Boston, MA 02115
    Circulation 127:673-80. 2013
  6. ncbi Elevated white cell count in acute coronary syndromes: relationship to variants in inflammatory and thrombotic genes
    Connie E Byrne
    Department of Clinical Pharmacology, Royal College of Surgeons in Ireland, 123 St Stephen s Green, Dublin 2, Ireland
    BMC Med Genet 5:13. 2004
  7. ncbi Antibiotic treatment of Chlamydia pneumoniae after acute coronary syndrome
    Christopher P Cannon
    Thrombolysis in Myocardial Infarction Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    N Engl J Med 352:1646-54. 2005
  8. ncbi Combination therapy in the management of mixed dyslipidaemia
    C P Cannon
    Thrombolysis in Myocardial Infarction TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    J Intern Med 263:353-65. 2008
  9. ncbi Cardiovascular disease and modifiable cardiometabolic risk factors
    Christopher P Cannon
    Harvard Medical School Cardiovascular Division, Brigham and Women s Hospital Boston, Massachusetts 02115, USA
    Clin Cornerstone 8:11-28. 2007
  10. ncbi Oral platelet glycoprotein IIb/IIIa receptor inhibitors--part II
    Christopher P Cannon
    Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA
    Clin Cardiol 26:401-6. 2003

Collaborators

Detail Information

Publications145 found, 100 shown here

  1. ncbi Evolving management of ST-segment elevation myocardial infarction: update on recent data
    Christopher P Cannon
    Thrombolysis in Myocardial Infarction TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA
    Am J Cardiol 98:10Q-21Q. 2006
    ..The new ACC/AHA recommendations support clopidogrel pretreatment and long-term therapy...
  2. ncbi Clinical trials update from the annual scientific session of the American College of Cardiology 2006
    Christopher P Cannon
    Thrombolysis in Myocardial Infarction Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA
    Am J Cardiol 98:36Q-41Q. 2006
  3. ncbi Introduction: rationale for tight control of hyperglycemia
    Christopher P Cannon
    The Thrombolysis in Myocardial Infarction (TIMI) Study Group, Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, 75 Francis Street, Boston, Massachusetts 02115, USA
    Am J Cardiol 99:1H-4H. 2007
  4. ncbi Outcomes of patients with acute coronary syndrome and previous coronary artery bypass grafting (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy [PROVE IT-TIMI 22] and the Aggrastat to Zocor [A to Z] trials)
    Emmanouil S Brilakis
    Cardiovascular Division, Department of Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA
    Am J Cardiol 102:552-8. 2008
    ..In conclusion, compared with patients with ACS without previous CABG, those with previous CABG have a higher risk for adverse cardiac events and may derive similar benefit from intensive statin therapy...
  5. ncbi Reduction in First and Recurrent Cardiovascular Events With Ticagrelor Compared With Clopidogrel in the PLATO Study
    Payal Kohli
    TIMI Study Group Cardiovascular Division, Brigham and Women s Hospital, 350 Longwood Avenue, 1 floor office, Boston, MA 02115
    Circulation 127:673-80. 2013
    ....
  6. ncbi Elevated white cell count in acute coronary syndromes: relationship to variants in inflammatory and thrombotic genes
    Connie E Byrne
    Department of Clinical Pharmacology, Royal College of Surgeons in Ireland, 123 St Stephen s Green, Dublin 2, Ireland
    BMC Med Genet 5:13. 2004
    ..We sought to identify whether pro-inflammatory genetic variants contributed to alterations in WBC and C-reactive protein (CRP) in an ACS population...
  7. ncbi Antibiotic treatment of Chlamydia pneumoniae after acute coronary syndrome
    Christopher P Cannon
    Thrombolysis in Myocardial Infarction Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    N Engl J Med 352:1646-54. 2005
    ..Pilot studies have suggested that antibiotic treatment may reduce the risk of cardiovascular events...
  8. ncbi Combination therapy in the management of mixed dyslipidaemia
    C P Cannon
    Thrombolysis in Myocardial Infarction TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    J Intern Med 263:353-65. 2008
    ..Careful monitoring is required when adding additional agents given the increased potential for drug interactions and side effects...
  9. ncbi Cardiovascular disease and modifiable cardiometabolic risk factors
    Christopher P Cannon
    Harvard Medical School Cardiovascular Division, Brigham and Women s Hospital Boston, Massachusetts 02115, USA
    Clin Cornerstone 8:11-28. 2007
    ..The new agents have the potential to significantly improve several CVD risk factors with a single medication and may provide clinicians with several new strategies to reduce the long-term risk of CVD...
  10. ncbi Oral platelet glycoprotein IIb/IIIa receptor inhibitors--part II
    Christopher P Cannon
    Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA
    Clin Cardiol 26:401-6. 2003
    ..Thus, agents targeted more "upstream" in platelet activation pathways may offer a more tolerable and efficacious approach to long-term antiplatelet therapy...
  11. ncbi Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy
    Christopher P Cannon
    Thrombolysis in Myocardial Infarction Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA
    J Am Coll Cardiol 48:438-45. 2006
    ..The purpose of this study was to conduct a meta-analysis that compares the reduction of cardiovascular outcomes with high-dose statin therapy versus standard dosing...
  12. ncbi Updated Strategies and Therapies for Reducing Ischemic and Vascular Events (STRIVE) unstable angina/non-ST elevation myocardial infarction critical pathway toolkit
    Christopher P Cannon
    TIMI Study Group, Brigham and Women s Hospital, Boston, MA 02115, USA
    Crit Pathw Cardiol 7:43-81. 2008
    ..These materials are being made available online to help physicians, nurses, and hospitals implement the new guidelines and thus improve the quality of care and outcomes for patients with ACS...
  13. ncbi Elderly patients with acute coronary syndromes: higher risk and greater benefit from antiplatelet therapy and/or interventional therapies
    Christopher P Cannon
    Cardiovascular Division, Department of Medicine, Brigham and Womens Hospital and Harvard Medical School, Boston, MA, USA
    Am J Geriatr Cardiol 12:259-62. 2003
    ..Thus, in unstable angina and non-ST elevation myocardial infarction, elderly patients are at higher risk and appear to derive particular benefit from more aggressive antithrombotic and interventional therapies...
  14. ncbi The next step in cardiovascular protection
    Christopher P Cannon
    TIMI Study Group, Brigham and Women s Hospital, 75 Francis Street, Boston, MA 02115, USA
    Atheroscler Suppl 4:3-9. 2003
    ..In 4162 ACS patients over a 2-year period, this trial will also evaluate the long-term effect of the quinolone antibiotic, gatifloxacin, in reducing cardiovascular events...
  15. ncbi Intensive versus moderate lipid lowering with statins after acute coronary syndromes
    Christopher P Cannon
    Thrombolysis in Myocardial Infarction TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    N Engl J Med 350:1495-504. 2004
    ..Lipid-lowering therapy with statins reduces the risk of cardiovascular events, but the optimal level of low-density lipoprotein (LDL) cholesterol is unclear...
  16. ncbi Balancing the benefit and risk of oral antiplatelet agents in coronary artery bypass surgery
    Christopher P Cannon
    Cardiovascular Division, Brigham and Women s Hospital, Boston, Massachusetts, USA
    Ann Thorac Surg 80:768-79. 2005
    ..Because the bleeding risk with aspirin is dose dependent, use of a low dose is preferred post-CABG...
  17. ncbi High-density lipoprotein cholesterol and residual cardiometabolic risk in metabolic syndrome
    Christopher P Cannon
    Harvard Medical School, TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, Boston, Massachusetts, USA
    Clin Cornerstone 8:S14-23. 2007
    ..Clinical trials with rimonabant, a CB1 receptor antagonist, have demonstrated significant weight loss as well as increased HDL-C levels and reduced triglyceride levels...
  18. ncbi Utilization of guidelines and computer-based technology to achieve optimal care in atherothrombotic vascular disease
    Christopher P Cannon
    Cardiovascular Division, Brigham and Women s Hospital, Boston, MA 02115, USA
    J Thromb Thrombolysis 17:45-9. 2004
    ....
  19. ncbi Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 tri
    Christopher P Cannon
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA
    J Am Coll Cardiol 50:1844-51. 2007
    ..Our goal was to compare the safety and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, with clopidogrel in patients with non-ST-segment elevation acute coronary syndromes (NSTE-ACS)...
  20. ncbi Critical pathways using platelet testing to potentially optimize the use of oral antiplatelet therapy
    Christopher P Cannon
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
    Am J Cardiol 98:33N-38N. 2006
    ..Several critical pathways are proposed that may assist clinicians in trying to ensure adequate platelet inhibition in these important clinical situations...
  21. ncbi Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison
    Christopher P Cannon
    Thrombolysis in Myocardial Infarction TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    Lancet 368:1771-81. 2006
    ..The MEDAL programme was designed to provide a precise estimate of thrombotic cardiovascular events with the COX-2 selective inhibitor etoricoxib versus the traditional NSAID diclofenac...
  22. ncbi Unstable angina and non-ST-elevation myocardial infarction: initial antithrombotic therapy and early invasive strategy
    Christopher P Cannon
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Mass 02115, USA
    Circulation 107:2640-5. 2003
  23. ncbi Risk stratification and prognostic factors in the post-myocardial infarction patient
    Christopher P Cannon
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    Am J Cardiol 102:13G-20G. 2008
    ..This article discusses the potential benefits of risk assessment tools in the management of post-MI patients with LVD...
  24. ncbi Improving acute coronary syndrome care: the ACC/AHA guidelines and critical pathways
    Christopher Cannon
    Cardiovascular Division, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115, USA
    J Invasive Cardiol 15:22B-27B; discussion 27B-29B. 2003
  25. ncbi Design of the Pravastatin or Atorvastatin Evaluation and Infection Therapy (PROVE IT)-TIMI 22 trial
    Christopher P Cannon
    Cardiovascular Division, Brigham and Women's Hospital, Boston, Massachusetts, USA
    Am J Cardiol 89:860-1. 2002
  26. ncbi Treatment of overweight and obesity: lifestyle, pharmacologic, and surgical options
    Christopher P Cannon
    Harvard Medical School Cardiovascular Division Brigham and Women s Hospital Boston, Massachusetts, USA
    Clin Cornerstone 9:55-68; discussion 69-71. 2009
    ..However, appropriate candidates for bariatric surgery must also be committed to long-term lifestyle changes...
  27. ncbi Effectiveness of clopidogrel versus aspirin in preventing acute myocardial infarction in patients with symptomatic atherothrombosis (CAPRIE trial)
    Christopher P Cannon
    Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA
    Am J Cardiol 90:760-2. 2002
  28. ncbi Acute coronary syndromes: risk stratification and initial management
    Christopher P Cannon
    Cardiovascular Division, Brigham and Women s Hospital, Boston, MA 02115, USA
    Cardiol Clin 23:401-9, v. 2005
    ..Thus, it is important for risk stratification to be a central part of all management of patients who have ACS...
  29. ncbi Oral platelet glycoprotein IIb/IIIa receptor inhibitors--Part I
    Christopher P Cannon
    Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
    Clin Cardiol 26:358-64. 2003
    ..If further development of this class of drugs is undertaken, formal dosing studies would have to establish an oral dosing strategy that achieves appropriately high (80-95% inhibition) and steady levels of inhibition...
  30. ncbi Design of the DEFINE trial: determining the EFficacy and tolerability of CETP INhibition with AnacEtrapib
    Christopher P Cannon
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, Boston, MA 02115, USA
    Am Heart J 158:513-519.e3. 2009
    ..Adverse effects on blood pressure, electrolytes, and aldosterone levels, seen with another drug in this class, have not been noted in studies of anacetrapib to date...
  31. ncbi Current use of aspirin and antithrombotic agents in the United States among outpatients with atherothrombotic disease (from the REduction of Atherothrombosis for Continued Health [REACH] Registry)
    Christopher P Cannon
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts, USA
    Am J Cardiol 105:445-52. 2010
    ..In conclusion, approximately 1/4 of US patients with vascular disease are not treated with aspirin for secondary prevention, and 15% are not treated with any antithrombotic agent...
  32. ncbi Strategies and Therapies for Reducing Ischemic and Vascular Events (STRIVE): updated standing orders for ST-segment elevation myocardial infarction and unstable angina/non-ST-segment elevation myocardial infarction
    Christopher P Cannon
    Cardiovascular Division, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    Crit Pathw Cardiol 9:55-81. 2010
    ..The updated STEMI and UA/NSTEMI standing orders and other tools are available to clinicians online on the STRIVE Web site...
  33. ncbi Cardiovascular disease and modifiable cardiometabolic risk factors
    Christopher P Cannon
    TIMI Study Group, Harvard Medical School, Cardiovascular Division, Brigham and Women s Hospital Boston, Massachusetts 02115, USA
    Clin Cornerstone 9:24-38; discussion 39-41. 2008
    ..The new agents have the potential to significantly improve several CVD risk factors with a single medication and may provide clinicians with several new strategies to reduce the long-term risk of CVD...
  34. ncbi Clinical trial design and patient demographics of the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) study program: cardiovascular outcomes with etoricoxib versus diclofenac in patients with osteoarthritis and rheumatoid arthritis
    Christopher P Cannon
    The TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    Am Heart J 152:237-45. 2006
    ..The MEDAL program will help to better define the risk-to-benefit ratio of 2 NSAIDs, that differ in their selectivity for COX-2, notably diclofenac and etoricoxib...
  35. ncbi Obesity-related cardiometabolic complications
    Christopher P Cannon
    Harvard Medical School, Brigham and Women s Hospital, Boston, Massachusetts, USA
    Clin Cornerstone 9:11-9; discussion 20-2. 2008
    ..Therapies directed at obesity, such as sibutramine and endocannabinoid receptor blockers (eg, rimonabant), have shown improvements in weight, blood pressure, the lipid profile, and glucose levels...
  36. ncbi Treatment algorithms and critical pathways for acute coronary syndromes
    Christopher P Cannon
    Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Boston, MA, USA
    Semin Vasc Med 3:425-32. 2003
    ..e. utilization of guideline recommended therapies. Several well-conducted studies, showing that particular use of critical pathways, can lead to improve quality of care...
  37. ncbi Small molecule glycoprotein IIb/IIIa receptor inhibitors as upstream therapy in acute coronary syndromes: insights from the TACTICS TIMI-18 trial
    Christopher P Cannon
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    J Am Coll Cardiol 41:43S-48S. 2003
    ..025). These results provide evidence to physicians that early GP IIb/IIIa inhibition in combination with a prompt invasive approach should be used more widely in UA/NSTEMI patients, particularly those at high risk...
  38. ncbi Updated Strategies and Therapies for Reducing Ischemic and Vascular Events (STRIVE) ST-segment elevation myocardial infarction critical pathway toolkit
    Christopher P Cannon
    TIMI Study Group, Brigham and Women s Hospital, Boston, MA 02115, USA
    Crit Pathw Cardiol 7:223-31. 2008
    ..The updated STEMI tools are available to clinicians online on the STRIVE Website...
  39. ncbi Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes
    Christopher P Cannon
    The TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, Boston, MA 02115, USA
    Am Heart J 156:826-32. 2008
    ....
  40. ncbi Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban
    C P Cannon
    Cardiovascular Division, Brigham and Women s Hospital, Boston, MA 02115, USA
    N Engl J Med 344:1879-87. 2001
    ..There is continued debate as to whether a routine, early invasive strategy is superior to a conservative strategy for the management of unstable angina and myocardial infarction without ST-segment elevation...
  41. ncbi Mixed dyslipidemia, metabolic syndrome, diabetes mellitus, and cardiovascular disease: clinical implications
    Christopher P Cannon
    Thrombolysis in Myocardial Infarction Study Group, Cardiovascular Division, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
    Am J Cardiol 102:5L-9L. 2008
    ....
  42. ncbi Safety of anacetrapib in patients with or at high risk for coronary heart disease
    Christopher P Cannon
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, Boston, MA 02115, USA
    N Engl J Med 363:2406-15. 2010
    ..Anacetrapib is a cholesteryl ester transfer protein inhibitor that raises high-density lipoprotein (HDL) cholesterol and reduces low-density lipoprotein (LDL) cholesterol...
  43. ncbi The prognostic value of serum myoglobin in patients with non-ST-segment elevation acute coronary syndromes. Results from the TIMI 11B and TACTICS-TIMI 18 studies
    James A de Lemos
    Thrombolysis in Myocardial Infarction TIMI Study Group, Reynolds Cardiovascular Clinical Research Center, University of Texas Southwestern Medical School, 5323 Harry Hines Boulevard, Dallas, TX 75390 9047, USA
    J Am Coll Cardiol 40:238-44. 2002
    ..The goal of this study was to define the prognostic value of serum myoglobin in patients with non-ST-elevation acute coronary syndromes (ACS)...
  44. ncbi Benefit of an early invasive management strategy in women with acute coronary syndromes
    Ruchira Glaser
    Department of Medicine, University of Pennsylvania, Philadelphia, USA
    JAMA 288:3124-9. 2002
    ..However, these studies were performed prior to the widespread use of platelet glycoprotein IIb/IIIa inhibitors and intracoronary stents...
  45. ncbi Clopidogrel: who, when, and how?
    Christopher P Cannon
    Thrombolysis in Myocardial Infarction TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts, USA
    Rev Cardiovasc Med 8:S27-34. 2007
    ..Clinical trial results and current guidelines recommend long-term treatment with clopidogrel for up to 1 year after PCI...
  46. ncbi Association of a pulsatile blood flow pattern on coronary arteriography and short-term clinical outcomes in acute myocardial infarction
    C Michael Gibson
    Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    J Am Coll Cardiol 43:1170-6. 2004
    ....
  47. ncbi Extent of ST-segment resolution after fibrinolysis adds improved risk stratification to clinical risk score for ST-segment elevation myocardial infarction
    James R Harkness
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, and Harvard Medical School, Boston, MA 02115, USA
    Am Heart J 159:55-62. 2010
    ..We sought to determine whether STRes provides incremental risk stratification to the TIMI risk score...
  48. ncbi Prognostic utility of apoB/AI, total cholesterol/HDL, non-HDL cholesterol, or hs-CRP as predictors of clinical risk in patients receiving statin therapy after acute coronary syndromes: results from PROVE IT-TIMI 22
    Kausik K Ray
    TIMI Study Group, Cardiovascular Division and the Department of Medicine, Brigham and Women s Hospital Harvard Medical School, Boston, MA 02115, USA
    Arterioscler Thromb Vasc Biol 29:424-30. 2009
    ....
  49. ncbi Myeloid-related protein 8/14 and the risk of cardiovascular death or myocardial infarction after an acute coronary syndrome in the Pravastatin or Atorvastatin Evaluation and Infection Therapy: Thrombolysis in Myocardial Infarction (PROVE IT-TIMI 22) trial
    David A Morrow
    Thrombolysis in Myocardial Infarction Study Group, Brigham and Women s Hospital, Boston, MA 02115, USA
    Am Heart J 155:49-55. 2008
    ..Elevated concentrations of MRP-8/14 are associated with a higher risk for future cardiovascular events in apparently healthy individuals but have not been assessed with respect to prognosis in patients with acute coronary syndrome...
  50. ncbi Effects of pretreatment with clopidogrel on nonemergent percutaneous coronary intervention after fibrinolytic administration for ST-segment elevation myocardial infarction: a Clopidogrel as Adjunctive Reperfusion Therapy-Thrombolysis in Myocardial Infarct
    C Michael Gibson
    TIMI Study Group and Cardiovascular Division, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02115, USA
    Am Heart J 155:133-9. 2008
    ..We sought to evaluate the effect of nonemergent PCI on mortality among patients with STEMI treated with fibrinolytic administration and the consequence of clopidogrel pretreatment on this effect...
  51. ncbi Association of impaired thrombolysis in myocardial infarction myocardial perfusion grade with ventricular tachycardia and ventricular fibrillation following fibrinolytic therapy for ST-segment elevation myocardial infarction
    C Michael Gibson
    TIMI Study Group, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02115, USA
    J Am Coll Cardiol 51:546-51. 2008
    ..The goal of this analysis was to evaluate the association of impaired Thrombolysis In Myocardial Infarction myocardial perfusion grade (TMPG) with sustained ventricular tachycardia (VT) or ventricular fibrillation (VF)...
  52. ncbi Reduction in recurrent cardiovascular events with intensive lipid-lowering statin therapy compared with moderate lipid-lowering statin therapy after acute coronary syndromes from the PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection T
    Sabina A Murphy
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts, USA
    J Am Coll Cardiol 54:2358-62. 2009
    ....
  53. ncbi Prognostic utility of heart-type fatty acid binding protein in patients with acute coronary syndromes
    James A de Lemos
    Cardiovascular Division, Brigham and Women's Hospital, 350 Longwood Ave, First Floor, Boston, Mass 02115, USA
    Circulation 114:550-7. 2006
    ....
  54. ncbi Lipoprotein-associated phospholipase A2 and its association with cardiovascular outcomes in patients with acute coronary syndromes in the PROVE IT-TIMI 22 (PRavastatin Or atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction)
    David A Morrow
    Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
    Circulation 113:1745-52. 2006
    ..At 30 days, Lp-PLA2 activity is significantly lowered with high-dose statin therapy and is associated with an increased risk of CV events independent of C-reactive protein and LDL cholesterol levels...
  55. ncbi Evaluation of the association of proximal coronary culprit artery lesion location with clinical outcomes in acute myocardial infarction
    Juhana Karha
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA
    Am J Cardiol 92:913-8. 2003
    ..In patients with a LAD culprit lesion, proximal lesion location is a multivariate correlate of adverse outcomes even after adjustment for coronary blood flow and other covariates...
  56. ncbi Association between plasma levels of monocyte chemoattractant protein-1 and long-term clinical outcomes in patients with acute coronary syndromes
    James A de Lemos
    TIMI Study Group, Donald W Reynolds Cardiovascular Clinical Research Center, The University of Texas, Southwestern Medical School, Dallas, TX 75390 9047, USA
    Circulation 107:690-5. 2003
    ..MCP-1 appears to play a critical role at multiple stages in atherosclerosis, including the initiation of the fatty streak, promotion of plaque instability, and remodeling after myocardial infarction...
  57. ncbi Effect of intensive lipid-lowering therapy on mortality after acute coronary syndrome (a patient-level analysis of the Aggrastat to Zocor and Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 trials)
    Sabina A Murphy
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts, USA
    Am J Cardiol 100:1047-51. 2007
    ..On the basis of these findings, 1 death was prevented for every 95 patients treated with high-dose statin therapy for 2 years. The results of this pooled analysis provide further evidence for early intensive statin therapy after ACS...
  58. ncbi Angiographic perfusion score in patients treated with PCI at late angiography following fibrinolytic administration for ST-segment elevation myocardial infarction is associated with morbidity and mortality at 30 days
    Yuri B Pride
    Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
    J Thromb Thrombolysis 26:106-12. 2008
    ..In STEMI patients treated with fibrinolytic therapy and scheduled for angiography later during hospital admission, however, the association of later indices of flow and perfusion with clinical outcomes has not been assessed...
  59. ncbi Office-based global cardiometabolic risk assessment: a simple tool incorporating nontraditional markers
    Subroto Acharjee
    Department of Medicine, SUNY at Buffalo School of Medicine, Buffalo, NY, USA
    Crit Pathw Cardiol 9:156-9. 2010
    ..As such, this could motivate both patients and physicians to work jointly toward reducing global cardiometabolic risk...
  60. ncbi Prior polyvascular disease: risk factor for adverse ischaemic outcomes in acute coronary syndromes
    Deepak L Bhatt
    VA Boston Healthcare System and Brigham and Women s Hospital, Boston, MA, USA
    Eur Heart J 30:1195-202. 2009
    ....
  61. ncbi Relationship between uncontrolled risk factors and C-reactive protein levels in patients receiving standard or intensive statin therapy for acute coronary syndromes in the PROVE IT-TIMI 22 trial
    Kausik K Ray
    Brigham and Women's Hospital/Harvard Medical School, Boston, Massachusetts, USA
    J Am Coll Cardiol 46:1417-24. 2005
    ....
  62. ncbi Regional and practice variation in adherence to guideline recommendations for secondary and primary prevention among outpatients with atherothrombosis or risk factors in the United States: a report from the REACH Registry
    Amit Kumar
    Department of Hospital Medicine, University of Massachusetts Medical School, Worcester, MA, USA
    Crit Pathw Cardiol 8:104-11. 2009
    ..Few data are available for outpatients in actual clinical practice, especially those without known heart disease treated by physicians trained in different specialties across the geographic regions of the United States...
  63. ncbi C-reactive protein and cardiovascular outcomes in smokers versus nonsmokers in non-ST-elevation acute coronary syndrome (from the TACTICS-TIMI 18 trial)
    Nazanin Moghbeli
    Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA
    Am J Cardiol 96:635-8. 2005
    ..0 vs 5.1 mg/L, p <0.001). CRP was associated with adverse cardiovascular outcomes in smokers and nonsmokers, even when adjusted for the presence of pulmonary disease...
  64. ncbi Angiographically evident thrombus following fibrinolytic therapy is associated with impaired myocardial perfusion in STEMI: a CLARITY-TIMI 28 substudy
    Ajay J Kirtane
    Cardiovascular Division, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
    Eur Heart J 27:2040-5. 2006
    ..This finding emphasizes the roles of platelet aggregation and distal embolization in the pathogenesis of microvascular dysfunction in STEMI...
  65. ncbi Distribution of traditional and novel risk factors and their relation to subsequent cardiovascular events in patients with acute coronary syndromes (from the PROVE IT-TIMI 22 trial)
    Subroto Acharjee
    Department of Medicine, SUNY at Buffalo School of Medicine, Buffalo, New York, USA
    Am J Cardiol 105:619-23. 2010
    ....
  66. ncbi Association of a history of systemic hypertension with mortality, thrombotic, and bleeding complications following non-ST-segment elevation acute coronary syndrome
    Raphaelle Dumaine
    Thrombolysis in Myocardial Infarction (TIMI) Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA 02115, USA
    J Clin Hypertens (Greenwich) 8:315-22. 2006
    ..45, 95% CI 1.03-2.06; p=0.036 at 30 days). It was concluded that chronic hypertension remains an independent marker for major short- and long-term cardiac adverse outcomes after non-ST-segment elevation acute coronary syndrome...
  67. ncbi Impact of gender on angiographic and clinical outcomes after fibrinolytic therapy in acute myocardial infarction
    Sabina A Murphy
    TIMI Study Group, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA
    Am J Cardiol 90:766-70. 2002
  68. ncbi Relation between soluble intercellular adhesion molecule-1, statin therapy, and long-term risk of clinical cardiovascular events in patients with previous acute coronary syndrome (from PROVE IT-TIMI 22)
    Kausik K Ray
    Brigham and Women's Hospital/Harvard Medical School, Boston, Massachusetts, USA
    Am J Cardiol 98:861-5. 2006
    ..In conclusion, in this large study of patients with ACS, we provide evidence that increased endothelial activation after ACS is independently associated with increased long-term risk of death, myocardial infarction, or recurrent ACS...
  69. ncbi Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison
    Loren Laine
    Division of Gastrointestinal and Liver Diseases, Department of Medicine, University of Southern California Keck School of Medicine, Los Angeles, CA 90033, USA
    Lancet 369:465-73. 2007
    ..Our aim was to assess the effects of these drugs on gastrointestinal outcomes in a population that includes patients taking gastrointestinal protective therapy...
  70. ncbi Association between duration of tirofiban therapy before percutaneous intervention and tissue level perfusion (a TACTICS-TIMI 18 substudy)
    C Michael Gibson
    Department of Medicine, Brigham and Women s Hospital, 350 Longwood Avenue, Boston, MA 02115, USA
    Am J Cardiol 94:492-4. 2004
    ....
  71. ncbi Critical pathways for management of patients with acute coronary syndromes: an assessment by the National Heart Attack Alert Program
    Christopher P Cannon
    Cardiovascular Division, Brigham and Women's Hospital, Boston, MA, USA
    Am Heart J 143:777-89. 2002
    ..Their use should improve the process and cost-effectiveness of care, but further research in this field is needed to determine whether these changes in the process of care will translate into improved clinical outcomes...
  72. ncbi Optimizing glycoprotein IIb/IIIa receptor antagonist use for the non-ST-segment elevation acute coronary syndromes: risk stratification and therapeutic intervention
    James L Januzzi
    Cardiology Division, Massachusetts General Hospital, Boston, Mass, USA
    Am Heart J 146:764-74. 2003
    ..In addition, we will consider appropriate methods/venues for use of GP IIb/IIIa receptor antagonism, including its role in an "early invasive" catheterization strategy...
  73. ncbi Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: results from the PROVE IT-TIMI 22 trial
    Kausik K Ray
    TIMI Study Group, Brigham and Women's Hospital/Harvard Medical School, Boston, Massachusetts 02115, USA
    J Am Coll Cardiol 46:1405-10. 2005
    ..In stable patients, intensive statin therapy provides long-term reduction in clinical events when compared with standard therapy. Thus, ACS patients should be started in-hospital and continued long-term on intensive statin therapy...
  74. ncbi Soluble CD40L: risk prediction after acute coronary syndromes
    Nerea Varo
    Donald W. Reynolds Cardiovascular Clinical Research Center, Brigham and Women's Hospital, Harvard Medical School, Boston, Mass 02115, USA
    Circulation 108:1049-52. 2003
    ..Notably, combined assessment of sCD40L with cTnI complements prognostic information for death and MI...
  75. ncbi Association of blood glucose with angiographic and clinical outcomes among patients with ST-segment elevation myocardial infarction (from the CLARITY-TIMI-28 study)
    Duane S Pinto
    Cardiovascular Division, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, USA
    Am J Cardiol 101:303-7. 2008
    ..IRA patency after fibrinolytic administration is related to admission glucose independent of clopidogrel administration...
  76. ncbi Sequential risk stratification using TIMI risk score and TIMI flow grade among patients treated with fibrinolytic therapy for ST-segment elevation acute myocardial infarction
    Dimitrios Karmpaliotis
    Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
    Am J Cardiol 94:1113-7. 2004
    ..High TRS at presentation is associated with abnormal myocardial perfusion, even after adjusting for possible confounders...
  77. ncbi Association of epicardial and tissue-level reperfusion with left ventricular end-diastolic pressures in ST-elevation myocardial infarction
    Ajay J Kirtane
    Department of Medicine, Beth Israel Deaconess Medical Center, USA
    J Thromb Thrombolysis 17:177-84. 2004
    ..8, p = 0.02) and 30-day congestive heart failure (OR 4.4, p = 0.02). In STEMI, angiographic indices of incomplete reperfusion are associated with an elevated LVEDP, and elevated LVEDP is associated with adverse clinical outcomes...
  78. ncbi Validated risk score predicts the development of congestive heart failure after presentation with unstable angina or non-ST-elevation myocardial infarction: results from OPUS-TIMI 16 and TACTICS-TIMI 18
    John V Wylie
    Division of Cardiology, Beth Israel Deaconess Medical Center, Department of Medicine, Harvard Medical School, Boston, Mass 02215, USA
    Am Heart J 148:173-80. 2004
    ..We developed and validated a risk score to predict which patients will develop CHF...
  79. ncbi Importance of intensive lipid lowering in acute coronary syndrome and percutaneous coronary intervention
    Amit Kumar
    UMass Marlborough Health System, Marlborough, Massachusetts, USA
    J Interv Cardiol 20:447-57. 2007
    ..This paper will review the current state of evidence from key recent statin trials in ACS and percutaneous coronary intervention (PCI) and discuss their significance for clinical practice...
  80. ncbi Heparin resistance in acute coronary syndromes
    Jonathan D Rich
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital and Harvard Medical School, 75 Francis St, Boston, MA 02115, USA
    J Thromb Thrombolysis 23:93-100. 2007
    ..Direct thrombin inhibitors may offer an advantage in more predictable anticoagulation...
  81. ncbi Early and long-term clinical outcomes associated with reinfarction following fibrinolytic administration in the Thrombolysis in Myocardial Infarction trials
    C Michael Gibson
    Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, 350 Longwood Avenue, 1st Floor, Boston, MA 02115, USA
    J Am Coll Cardiol 42:7-16. 2003
    ..We hypothesized that early recurrent myocardial infarction (MI) following fibrinolytic administration would be assessed with higher mortality at both 30 days and 2 years...
  82. ncbi Synergistic relationship between hyperglycaemia and inflammation with respect to clinical outcomes in non-ST-elevation acute coronary syndromes: analyses from OPUS-TIMI 16 and TACTICS-TIMI 18
    Kausik K Ray
    The TIMI Study Group and Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, 350 Longwood Avenue, Boston, MA 02115, USA
    Eur Heart J 28:806-13. 2007
    ..To investigate the relationship between diabetes and inflammation and the potentially synergistic relationship between hyperglycaemia and inflammation on clinical outcomes in non ST-elevation ACS...
  83. ncbi Predictors of mortality, coronary angiography, and revascularization in unstable angina pectoris and acute non-ST elevation myocardial infarction (the TIMI III Registry)
    Peter J Sharis
    Cardiovascular Division and Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA 02215, USA
    Am J Cardiol 90:1154-6. 2002
  84. ncbi Time for contrast material to traverse the epicardial artery and the myocardium in ST-segment elevation acute myocardial infarction versus unstable angina pectoris/non-ST-elevation acute myocardial infarction
    Graham C Wong
    TIMI Study Group and the Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA
    Am J Cardiol 91:1163-7. 2003
    ..These data provide insight into potential mechanistic differences between these 2 clinical syndromes...
  85. ncbi Effect of statin dose on incidence of atrial fibrillation: data from the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) and Aggrastat to Zocor (A to Z) trials
    Dalton S McLean
    Cardiovascular Division, Department of Medicine, Thrombolysis in Myocardial Infarction Study Group, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    Am Heart J 155:298-302. 2008
    ..Several observational studies have suggested that statins, presumably through their anti-inflammatory properties, decrease the risk of AF...
  86. ncbi Gender differences in aspirin use among adults with coronary heart disease in the United States
    Alexander R Opotowsky
    Department of Medicine, Brigham and Women s Hospital, Boston, MA 02115, USA
    J Gen Intern Med 22:55-61. 2007
    ..The presence of gender differences in aspirin use for secondary prevention is less clear...
  87. ncbi Elevations in troponin T and I are associated with abnormal tissue level perfusion: a TACTICS-TIMI 18 substudy. Treat Angina with Aggrastat and Determine Cost of Therapy with an Invasive or Conservative Strategy-Thrombolysis in Myocardial Infarction
    Graham C Wong
    Department of Medicine, Brigham and Women's Hospital, Boston, Mass, USA
    Circulation 106:202-7. 2002
    ..Independent of the presence of thrombus and abnormal flow in the epicardial artery, impaired tissue level perfusion is associated with a 1.8-fold increased risk of cTnT elevation...
  88. ncbi Association of culprit lesion calcium with angiographic and clinical outcomes in patients with ST-elevation myocardial infarction treated with fibrinolytic therapy
    Ajay J Kirtane
    Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
    Am J Cardiol 95:337-42. 2005
    ..2, p = 0.045). CLC is independently associated with indexes of poorer epicardial flow and a higher incidence of adverse clinical outcomes after fibrinolytic administration in patients who have ST-elevation myocardial infarction...
  89. ncbi Serum blood urea nitrogen as an independent marker of subsequent mortality among patients with acute coronary syndromes and normal to mildly reduced glomerular filtration rates
    Ajay J Kirtane
    Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts
    J Am Coll Cardiol 45:1781-6. 2005
    ..CONCLUSIONS: Among patients with unstable coronary syndromes and predominantly normal or mildly reduced GFR, an elevated BUN is associated with increased mortality, independent of sCr-based estimates of GFR and other biomarkers...
  90. ncbi Early dynamic risk stratification with baseline troponin levels and 90-minute ST-segment resolution to predict 30-day cardiovascular mortality in ST-segment elevation myocardial infarction: analysis from CLopidogrel as Adjunctive ReperfusIon TherapY (CLAR
    Matthew W Sherwood
    TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    Am Heart J 159:964-971.e1. 2010
    ..The incremental prognostic use of the initial magnitude of troponin elevation and its value in conjunction with ST-segment resolution (STRes) in ST elevation myocardial infarction (STEMI) is less well defined...
  91. ncbi Acute coronary syndromes and diabetes: Is intensive lipid lowering beneficial? Results of the PROVE IT-TIMI 22 trial
    Shaheeda Ahmed
    The TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, Harvard Medical School, 350 Longwood Avenue, First Floor, Boston, MA 02115, USA
    Eur Heart J 27:2323-9. 2006
    ..The impact of intensive lipid lowering therapy with statins in acute coronary syndrome (ACS) patients with diabetes mellitus (DM) is not well characterized...
  92. ncbi Physician practice patterns in acute coronary syndromes: an initial report of an individual quality improvement program
    Christopher P Cannon
    Cardiovascular Division, Brigham and Women s Hospital, Boston, MA, USA
    Crit Pathw Cardiol 9:23-9. 2010
    ..This fact may reflect several barriers to PI, such as: (1) lack of time to collect and submit data, (2) the belief that current practices do not need to be improved, and (3) the need for system-based improvements...
  93. ncbi Benefits of achieving the NCEP optional LDL-C goal among elderly patients with ACS
    Kausik K Ray
    The TIMI Study Group and Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital Harvard Medical School, Boston, MA 02115, USA
    Eur Heart J 27:2310-6. 2006
    ..To assess the efficacy and safety of the achievement of the NCEP goal of LDL-C <1.8 mmol/L in elderly patients with ACS...
  94. ncbi Impact of diabetes mellitus on epicardial and microvascular flow after fibrinolytic therapy
    Brad G Angeja
    Cardiovascular Division, Department of Medicine, University of California, San Francisco, Calif 94143, USA
    Am Heart J 144:649-56. 2002
    ..We studied the angiographic and electrocardiographic responses to thrombolytic agents in patients with diabetes; in particular ST-segment resolution as a measure of microvascular flow...
  95. ncbi Early initiation of lipid-lowering therapy for acute coronary syndromes improves compliance with guideline recommendations: observations from the Orbofiban in Patients with Unstable Coronary Syndromes (OPUS-TIMI 16) trial
    Charles S Smith
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Mass 02115, USA
    Am Heart J 149:444-50. 2005
    ....
  96. ncbi Rimonabant: a cannabinoid receptor type 1 blocker for management of multiple cardiometabolic risk factors
    Eli V Gelfand
    Cardiovascular Division, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
    J Am Coll Cardiol 47:1919-26. 2006
    ..As an agent with a novel mechanism of action, rimonabant has a potential to be a useful adjunct to lifestyle and behavior modification in treatment of multiple cardiometabolic risk factors, including abdominal obesity and smoking...
  97. ncbi Optimal timing of intervention in non-ST-segment elevation acute coronary syndromes: insights from the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA guidelines) Regist
    Jason W Ryan
    Cardiovascular Division, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    Circulation 112:3049-57. 2005
    ..Using weekend status as an instrumental variable, we found no significant benefit to early catheterization, although we could not exclude an important risk reduction, particularly for catheterization within 12 hours of presentation...
  98. ncbi Early time to benefit with intensive statin treatment: could it be the pleiotropic effects?
    Kausik K Ray
    Thrombolysis in Myocardial Infarction Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA
    Am J Cardiol 96:54F-60F. 2005
    ..The very early benefits of statin therapy appeared to be correlated with CRP reductions, which may relate to the intensity of the pleiotropic effects of statins...
  99. ncbi Antibiotics for secondary prevention of coronary artery disease: an ACES hypothesis but we need to PROVE IT
    Eli V Gelfand
    Cardiovascular Division, Beth Israel Deaconess Medical Center, Boston, Mass, USA
    Am Heart J 147:202-9. 2004
  100. ncbi Direct comparison of characteristics, treatment, and outcomes of patients enrolled versus patients not enrolled in a clinical trial at centers participating in the TIMI 9 Trial and TIMI 9 Registry
    Maria Cecilia Bahit
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Boston, Mass 02115, USA
    Am Heart J 145:109-17. 2003
    ....
  101. ncbi Relation between myocardial infarct size and ventricular tachyarrhythmia among patients with preserved left ventricular ejection fraction following fibrinolytic therapy for ST-segment elevation myocardial infarction
    Yuri B Pride
    Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
    Am J Cardiol 104:475-9. 2009
    ....